136 related articles for article (PubMed ID: 2156824)
1. Biochemical and functional characterization of human tissue-type plasminogen activator variants obtained by deletion and/or duplication of structural/functional domains.
Lijnen HR; Nelles L; Van Hoef B; De Cock F; Collen D
J Biol Chem; 1990 Apr; 265(10):5677-83. PubMed ID: 2156824
[TBL] [Abstract][Full Text] [Related]
2. Characterization of domain deletion and/or duplication mutants of a recombinant chimera of tissue-type plasminogen activator and urokinase-type plasminogen activator (rt-PA/u-PA).
Nelles L; Lijnen HR; Van Nuffelen A; Demarsin E; Collen D
Thromb Haemost; 1990 Aug; 64(1):53-60. PubMed ID: 2148847
[TBL] [Abstract][Full Text] [Related]
3. Biochemical and functional characterization of human tissue-type plasminogen activator variants with mutagenized kringle domains.
Collen D; Lijnen HR; Bulens F; Vandamme AM; Tulinsky A; Nelles L
J Biol Chem; 1990 Jul; 265(21):12184-91. PubMed ID: 2115513
[TBL] [Abstract][Full Text] [Related]
4. Biochemical and biologic properties of rt-PA del (K296-G302), a recombinant human tissue-type plasminogen activator deletion mutant resistant to plasminogen activator inhibitor-1.
Li XK; Lijnen HR; Nelles L; Van Hoef B; Stassen JM; Collen D
Blood; 1992 Jan; 79(2):417-29. PubMed ID: 1730087
[TBL] [Abstract][Full Text] [Related]
5. Variants of human tissue-type plasminogen activator. Fibrin binding, fibrinolytic, and fibrinogenolytic characterization of genetic variants lacking the fibronectin finger-like and/or the epidermal growth factor domains.
Larsen GR; Henson K; Blue Y
J Biol Chem; 1988 Jan; 263(2):1023-9. PubMed ID: 3121618
[TBL] [Abstract][Full Text] [Related]
6. The position of the structurally autonomous kringle 2 domain influences the functional features of tissue-type plasminogen activator.
Bakker AH; Rehberg EF; Marotti KR; Verheijen JH
Protein Eng; 1995 Mar; 8(3):293-300. PubMed ID: 7479691
[TBL] [Abstract][Full Text] [Related]
7. Introduction of lysine and clot binding properties in the kringle one domain of tissue-type plasminogen activator.
Bakker AH; van der Greef W; Rehberg EF; Marotti KR; Verheijen JH
J Biol Chem; 1993 Sep; 268(25):18496-501. PubMed ID: 8395505
[TBL] [Abstract][Full Text] [Related]
8. Replacement of finger and growth factor domains of tissue plasminogen activator with plasminogen kringle 1. Biochemical and pharmacological characterization of a novel chimera containing a high affinity fibrin-binding domain linked to a heterologous protein.
Langer-Safer PR; Ahern TJ; Angus LB; Barone KM; Brenner MJ; Horgan PG; Morris GE; Stoudemire JB; Timony GA; Larsen GR
J Biol Chem; 1991 Feb; 266(6):3715-23. PubMed ID: 1847387
[TBL] [Abstract][Full Text] [Related]
9. Biochemical, thrombolytic and pharmacokinetic properties of rt-PA P47G, K49N, a substitution variant of human tissue-type plasminogen activator.
Nelles L; Li XK; Vanlinthout I; De Cock F; Lijnen HR; Collen D
Thromb Haemost; 1992 Apr; 67(4):445-52. PubMed ID: 1631793
[TBL] [Abstract][Full Text] [Related]
10. Plasmin-mediated fibrinolysis by variant recombinant tissue plasminogen activators.
Urano S; Metzger AR; Castellino FJ
Proc Natl Acad Sci U S A; 1989 Apr; 86(8):2568-71. PubMed ID: 2523073
[TBL] [Abstract][Full Text] [Related]
11. The specific roles of finger and kringle 2 domains of tissue-type plasminogen activator during in vitro fibrinolysis.
Horrevoets AJ; Smilde A; de Vries C; Pannekoek H
J Biol Chem; 1994 Apr; 269(17):12639-44. PubMed ID: 8175674
[TBL] [Abstract][Full Text] [Related]
12. Autonomous functions of structural domains on human tissue-type plasminogen activator.
van Zonneveld AJ; Veerman H; Pannekoek H
Proc Natl Acad Sci U S A; 1986 Jul; 83(13):4670-4. PubMed ID: 3088564
[TBL] [Abstract][Full Text] [Related]
13. Characterization of a fusion protein consisting of amino acids 1 to 263 of tissue-type plasminogen activator and amino acids 144 to 411 of urokinase-type plasminogen activator.
Nelles L; Lijnen HR; Collen D; Holmes WE
J Biol Chem; 1987 Aug; 262(22):10855-62. PubMed ID: 2956260
[TBL] [Abstract][Full Text] [Related]
14. Structure and function of human tissue-type plasminogen activator (t-PA).
van Zonneveld AJ; Veerman H; MacDonald ME; van Mourik JA; Pannekoek H
J Cell Biochem; 1986; 32(3):169-78. PubMed ID: 3097031
[TBL] [Abstract][Full Text] [Related]
15. Kinetic characterization of tissue-type plasminogen activator (t-PA) and t-PA deletion mutants.
de Vries C; Veerman H; Nesheim ME; Pannekoek H
Thromb Haemost; 1991 Mar; 65(3):280-5. PubMed ID: 1904654
[TBL] [Abstract][Full Text] [Related]
16. Biochemical and biological properties of a recombinant tissue-type plasminogen activator derived from the rat JMI-229 cell line.
Lijnen HR; Webb PD; Van Hoef B; De Cock F; Stassen JM; Prior SD; Collen D
Thromb Haemost; 1992 Feb; 67(2):239-47. PubMed ID: 1621244
[TBL] [Abstract][Full Text] [Related]
17. Functional effects of asparagine-linked oligosaccharide on natural and variant human tissue-type plasminogen activator.
Hansen L; Blue Y; Barone K; Collen D; Larsen GR
J Biol Chem; 1988 Oct; 263(30):15713-9. PubMed ID: 3139674
[TBL] [Abstract][Full Text] [Related]
18. Structural determinants of the noncatalytic chain of tissue-type plasminogen activator that modulate its association rate with plasminogen activator inhibitor-1.
de Serrano VS; Castellino FJ
J Biol Chem; 1990 Jun; 265(18):10473-8. PubMed ID: 2113057
[TBL] [Abstract][Full Text] [Related]
19. Characterization of a chimaeric plasminogen activator obtained by insertion of the second kringle structure of tissue-type plasminogen activator (amino acids 173 through 262) between residues Asp130 and Ser139 of urokinase-type plasminogen activator.
Lijnen HR; Piérard L; Reff ME; Gheysen D
Thromb Res; 1988 Dec; 52(5):431-41. PubMed ID: 3146822
[TBL] [Abstract][Full Text] [Related]
20. Domain-domain interactions in hybrids of tissue-type plasminogen activator and urokinase-type plasminogen activator.
Bakker AH; Nieuwenbroek NM; Verheijen JH
Protein Eng; 1995 Dec; 8(12):1295-1302. PubMed ID: 8869642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
